Time called on Pfizer–AstraZeneca deal


Pfizer’s pursuit of a pharmaceutical megamerger with AstraZeneca (AZ) has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK’s takeover rules.

The City Code on Takeovers and Mergers allows Pfizer to make a new approach to AZ after a six month cooling off period, or AZ can invite Pfizer to negotiate after three months. Given the Anglo-Swedish firm’s steadfast refusal to entertain Pfizer’s advances, the latter option seems unlikely. ‘We welcome the opportunity to continue building on the momentum we have already demonstrated as an independent company,’ AZ’s chairman Leif Johansson said in a statement after the withdrawal.

Pfizer, in its turn, is leaving the door open. ‘We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us’ said chief executive Ian Read in the withdrawal statement. The value and attactiveness of any new offer will depend strongly on how well AZ lives up to predictions about forthcoming drugs made by the board to justify its refusal of this deal. 


Related Content

Pfizer presses hard for AstraZeneca deal

14 May 2014 Business

news image

Executives face down international controversy over tax schemes and previous post-merger record

Pfizer courts AstraZeneca megamerger

29 April 2014 Business

news image

AZ rebuffs public dealmongering

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint